NextCell Pharma AB (NXTCL) - Cash Flow Conversion Efficiency

Latest as of August 2025: -0.162x

Based on the latest financial reports, NextCell Pharma AB (NXTCL) has a cash flow conversion efficiency ratio of -0.162x as of August 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-10.77 Million ≈ $-1.16 Million USD) by net assets (Skr66.39 Million ≈ $7.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NXTCL defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

NextCell Pharma AB - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how NextCell Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

NextCell Pharma AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of NextCell Pharma AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Bionano Genomics Inc NASDAQ:BNGO	-0.094x
Nukkleus Inc NASDAQ:NUKK	0.033x
Bodhi Tree Multimedia Limited NSE:BTML	0.001x
FASING SA WAR:FSG	0.009x
Acumentis Group Ltd AU:ACU	0.081x
BTM Resources Bhd KLSE:7188	-0.033x
CytoMed Therapeutics Limited Ordinary Shares NASDAQ:GDTC	-0.299x
Waja Konsortium Bhd KLSE:0102	-0.118x

Annual Cash Flow Conversion Efficiency for NextCell Pharma AB (2015–2025)

The table below shows the annual cash flow conversion efficiency of NextCell Pharma AB from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see market value of NextCell Pharma AB.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-08-31	Skr66.39 Million ≈ $7.14 Million	Skr-38.86 Million ≈ $-4.18 Million	-0.585x	-4.75%
2024-08-31	Skr67.60 Million ≈ $7.27 Million	Skr-37.78 Million ≈ $-4.07 Million	-0.559x	+3.43%
2023-08-31	Skr75.73 Million ≈ $8.15 Million	Skr-43.83 Million ≈ $-4.72 Million	-0.579x	-100.73%
2022-08-31	Skr115.54 Million ≈ $12.43 Million	Skr-33.31 Million ≈ $-3.58 Million	-0.288x	-69.19%
2021-08-31	Skr150.09 Million ≈ $16.15 Million	Skr-25.58 Million ≈ $-2.75 Million	-0.170x	+76.44%
2020-08-31	Skr26.22 Million ≈ $2.82 Million	Skr-18.96 Million ≈ $-2.04 Million	-0.723x	+24.99%
2019-08-31	Skr22.96 Million ≈ $2.47 Million	Skr-22.13 Million ≈ $-2.38 Million	-0.964x	+64.13%
2018-08-31	Skr5.04 Million ≈ $542.53K	Skr-13.55 Million ≈ $-1.46 Million	-2.688x	-246.01%
2017-08-31	Skr19.07 Million ≈ $2.05 Million	Skr-14.82 Million ≈ $-1.59 Million	-0.777x	+52.74%
2016-08-31	Skr6.76 Million ≈ $728.00K	Skr-11.12 Million ≈ $-1.20 Million	-1.644x	-106.93%
2015-08-31	Skr9.77 Million ≈ $1.05 Million	Skr-7.76 Million ≈ $-835.27K	-0.794x	--

About NextCell Pharma AB

ST:NXTCL Sweden Biotechnology

Market Cap

$12.63 Million

Skr117.41 Million SEK

Market Cap Rank

#26461 Global

#569 in Sweden

Share Price

Skr1.05

Change (1 day)

-1.13%

52-Week Range

Skr0.67 - Skr1.69

All Time High

Skr29.60